Literature DB >> 16847058

Roles for UDP-GlcNAc 2-epimerase/ManNAc 6-kinase outside of sialic acid biosynthesis: modulation of sialyltransferase and BiP expression, GM3 and GD3 biosynthesis, proliferation, and apoptosis, and ERK1/2 phosphorylation.

Zhiyun Wang1, Zhonghui Sun, Adrienne V Li, Kevin J Yarema.   

Abstract

Roles for UDP-GlcNAc 2-epimerase/ManNAc 6-kinase (GNE) beyond controlling flux into the sialic acid biosynthetic pathway by converting UDP-GlcNAc to N-acetylmannosamine are described in this report. Overexpression of recombinant GNE in human embryonic kidney (HEK AD293) cells led to an increase in mRNA levels for ST3Gal5 (GM3 synthase) and ST8Sia1 (GD3 synthase) as well as the biosynthetic products of these sialyltransferases, the GM3 and GD3 gangliosides. Conversely, down-regulation of GNE by RNA interference methods had the opposite, but consistent, effect of lowering ST3Gal5 and ST8Sia1 mRNAs and reducing GM3 and GD3 levels. Control experiments ensured that GNE-mediated changes in sialyltransferase expression and ganglioside biosynthesis were not the result of altered flux through the sialic acid pathway. Interestingly, exogenous GM3 and GD3 also changed the expression of GNE and led to reduced ST3Gal5 and ST8Sia1 mRNA levels, demonstrating a reciprocating feedback mechanism where gangliosides regulate upstream biosynthetic enzymes. Cellular responses to the GNE-mediated changes in ST3Gal5 and ST8Sia1 expression and GM3 and GD3 levels were investigated next. Conditions that led to reduced ganglioside production (e.g. short hairpin RNA exposure) stimulated proliferation, whereas conditions that resulted in increased ganglioside levels (e.g. recombinant GNE and exogenous gangliosides) led to reduced proliferation with a concomitant increase in apoptosis. Finally, changes to BiP expression and ERK1/2 phosphorylation consistent with apoptosis and proliferation, respectively, were observed. These results provide examples of specific biochemical pathways, other than sialic acid metabolism, that are influenced by GNE.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16847058     DOI: 10.1074/jbc.M604903200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  46 in total

1.  Metabolic flux increases glycoprotein sialylation: implications for cell adhesion and cancer metastasis.

Authors:  Ruben T Almaraz; Yuan Tian; Rahul Bhattarcharya; Elaine Tan; Shih-Hsun Chen; Matthew R Dallas; Li Chen; Zhen Zhang; Hui Zhang; Konstantinos Konstantopoulos; Kevin J Yarema
Journal:  Mol Cell Proteomics       Date:  2012-03-28       Impact factor: 5.911

2.  Metabolic oligosaccharide engineering with N-Acyl functionalized ManNAc analogs: cytotoxicity, metabolic flux, and glycan-display considerations.

Authors:  Ruben T Almaraz; Udayanath Aich; Hargun S Khanna; Elaine Tan; Rahul Bhattacharya; Shivam Shah; Kevin J Yarema
Journal:  Biotechnol Bioeng       Date:  2011-11-21       Impact factor: 4.530

3.  Targeting pro-invasive oncogenes with short chain fatty acid-hexosamine analogues inhibits the mobility of metastatic MDA-MB-231 breast cancer cells.

Authors:  Christopher T Campbell; Udayanath Aich; Christopher A Weier; Jean J Wang; Sean S Choi; Mary M Wen; Katharina Maisel; Srinivasa-Gopalan Sampathkumar; Kevin J Yarema
Journal:  J Med Chem       Date:  2008-12-25       Impact factor: 7.446

4.  The sialyltransferase ST3GAL6 influences homing and survival in multiple myeloma.

Authors:  Siobhan V Glavey; Salomon Manier; Alessandro Natoni; Antonio Sacco; Michele Moschetta; Michaela R Reagan; Laura S Murillo; Ilyas Sahin; Ping Wu; Yuji Mishima; Yu Zhang; Wenjing Zhang; Yong Zhang; Gareth Morgan; Lokesh Joshi; Aldo M Roccaro; Irene M Ghobrial; Michael E O'Dwyer
Journal:  Blood       Date:  2014-07-24       Impact factor: 22.113

5.  Biochemical characterization of human and murine isoforms of UDP-N-acetylglucosamine 2-epimerase/N-acetylmannosamine kinase (GNE).

Authors:  Stefan O Reinke; Colin Eidenschink; Chris M Jay; Stephan Hinderlich
Journal:  Glycoconj J       Date:  2008-09-23       Impact factor: 2.916

6.  Prophylactic treatment with sialic acid metabolites precludes the development of the myopathic phenotype in the DMRV-hIBM mouse model.

Authors:  May Christine V Malicdan; Satoru Noguchi; Yukiko K Hayashi; Ikuya Nonaka; Ichizo Nishino
Journal:  Nat Med       Date:  2009-06       Impact factor: 53.440

7.  Ganglioside GM3 levels are altered in a mouse model of HIBM: GM3 as a cellular marker of the disease.

Authors:  Thomas Paccalet; Zoé Coulombe; Jacques P Tremblay
Journal:  PLoS One       Date:  2010-04-07       Impact factor: 3.240

8.  Hereditary Inclusion Body Myopathy (HIBM2).

Authors:  Chris M Jay; Nick Levonyak; Gregory Nemunaitis; Phillip B Maples; John Nemunaitis
Journal:  Gene Regul Syst Bio       Date:  2009-10-21

9.  Preclinical assessment of wt GNE gene plasmid for management of hereditary inclusion body myopathy 2 (HIBM2).

Authors:  Chris Jay; Gregory Nemunaitis; John Nemunaitis; Neil Senzer; Stephan Hinderlich; Daniel Darvish; Julie Ogden; John Eager; Alex Tong; Phillip B Maples
Journal:  Gene Regul Syst Bio       Date:  2008-06-20

10.  Moderate strength (0.23-0.28 T) static magnetic fields (SMF) modulate signaling and differentiation in human embryonic cells.

Authors:  Zhiyun Wang; Anshu Sarje; Pao-Lin Che; Kevin J Yarema
Journal:  BMC Genomics       Date:  2009-08-04       Impact factor: 3.969

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.